Evidence map›Paper›PMID 35209106›Full record

ArticleMolecules (Basel, Switzerland)2022

Protective Effect of Quercetin 3-

Daniel Muñoz-Reyes, Alfredo G Casanova, Ana María González-Paramás, Ángel Martín, Celestino Santos-Buelga, Ana I Morales, Francisco J López-Hernández, Marta Prieto

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Antibacterial and Antimycotic Activity ofPharmaceuticals (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Pharmacological Activity of Quercetin: An Updated Review.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Daniel Muñoz-ReyesToxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-8464-1996
Alfredo G CasanovaToxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-0725-6637
Ana María González-ParamásPolyphenols Research Group (GIP-USAL), Nutrition and Bromatology Unit, Faculty of Pharmacy, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-5477-0703
Ángel MartínHigh Pressure Processes Group, BioEcoUVa, Bioeconomy Research Institute, Department of Chemical Engineering and Environmental Technology, Universidad de Valladolid, 47011 Valladolid, Spain.
Celestino Santos-BuelgaPolyphenols Research Group (GIP-USAL), Nutrition and Bromatology Unit, Faculty of Pharmacy, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-6592-5299
Ana I MoralesToxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-6836-6138
Francisco J López-HernándezDepartment of Physiology and Pharmacology, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-7778-7495
Marta PrietoToxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-2540-4461
Universidad de Salamanca · ESUniversidad de Valladolid · ES

Funding

Consejería de Educación, Junta de Castilla y León Project SA093P20Fundación FUESCYL-Banco Santander Ed. 2014-2015 Desafío UNIV-EMPFundación General de la Universidad de Salamanca, Fondo Europeo de Desarrollo Regional (FEDER) y la Junta de Castilla y León Ed. 2015 Lanzadera TCJunta de Castilla y León VA225U14Spanish Ministerio de Ciencia, Innovación Project PID2019-106167RB-I00Strategic Research Programs for Units of Excellence from Junta de Castilla y León CLU-2018-04
6 · The paper itself

Abstract

Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3-

Indexed as

AnimalsCell LineCells, CulturedChromatography, High Pressure LiquidCisplatinCytoprotectionEpithelial CellsGlomerular Filtration RateKidney Function TestsKidney TubulesProtective AgentsQuercetinRatsCisplatinProtective AgentsQuercetinquercetin 3-O-glucuronidecisplatincytoprotectionnephrotoxicityquercetinquercetin 3-O-glucuronide

Identifiers

PMID35209106
PMCPMC8880316
OpenAlexW4212835294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.